Newsfeeds - Spark Newswire

1 minute read

Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR

June 15, 9:07 AM

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) --  Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate

SILK

1 minute read

Analyst Ratings

Analyst Ratings for Silk Road Medical

By Benzinga Insights

May 17, 10:24 AM

Silk Road Medical (NASDAQ:SILK) has observed the following analyst ratings within the last quarter:

SILK

1 minute read

Citigroup Maintains Neutral on Silk Road Medical, Lowers Price Target to $33

By Benzinga Newsdesk

May 17, 9:04 AM

Citigroup analyst Joanne Wuensch maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and lowers the price target from $44 to $33.

SILK

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

May 4, 4:36 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

3 minute read

31 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

May 2, 12:17 PM

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition.

ACCD

2 minute read

Silk Road Medical Reports FDA Approval Of Expanded Indications For ENROUTE Transcarotid Stent System

By Benzinga Newsdesk

May 2, 8:39 AM

Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that that the U.S. Food and Drug Administration (FDA) approved expanded

SILK

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 6, 2022

By Benzinga Insights

April 6, 10:16 AM

Upgrades

ABMD

1 minute read

Citigroup Maintains Neutral on Silk Road Medical, Lowers Price Target to $37

By Benzinga Newsdesk

February 25, 8:42 AM

Citigroup analyst Joanne Wuensch maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and lowers the price target from $45 to $37.

SILK

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

February 20, 9:06 AM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

January 14, 1:30 PM

During Friday's session, 445 companies made new 52-week lows.

AAOI